
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 5, 2019**

MARIMED INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-54433
(Commission
File Number)

27-4672745
(IRS Employer
Identification No.)

10 Oceana Way, Norwood, Massachusetts
(Address of principal executive offices)

02062
(Zip Code)

Registrant's telephone number, including area code: **(617) 795-5140**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class
Not Applicable.

Ticker symbol(s)
Not Applicable.

Name of each exchange on which registered
Not Applicable.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2019, the Registrant received a letter from Thomas Kidrin resigning from the Registrant's board of directors, effective immediately. The letter, a copy of which is filed as Exhibit 99.1 to this Current Report, states that Mr. Kidrin's resignation was "due to a dispute over outstanding matters." No further explanation was provided.

As previously reported in its Forms 10-K and 10-Q, the Registrant contends that an employment agreement with Mr. Kidrin is not valid. The Registrant is currently evaluating commencement of legal action against Mr. Kidrin.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit</u>	<u>Description</u>
----------------	--------------------

99.1	Resignation letter from Thomas Kidrin dated June 5, 2019
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARIMED INC.

Dated: June 11, 2019

By: /s/ ROBERT FIREMAN
Robert Fireman, CEO

EXHIBIT INDEX

Exhibit **Description**

99.1 [Resignation letter from Thomas Kidrin dated June 5, 2019](#)

Thom Kidrin
11 Royal Road
Brookline MA 02445

June 5, 2019

Board of Directors
MariMed Inc.
10 Oceana Way
Norwood, Massachusetts 02062

Gentlemen:

You are hereby advised that, effective as of the date of this letter, June 5, 2019, I hereby resign as a director of MariMed Inc. (the "Company"). My resignation is due to a dispute over outstanding matters.

I understand that my resignation will trigger an obligation of the Company to file a Current Report on Form 8-K and that this letter will be included in such filing as an exhibit thereto.

Very truly yours,



Thomas Kidrin
